CDC and State Department Award XpresTest $38.8M for Disease Response

The federal awards to XpresTest, a subsidiary of XWELL, combine two distinct public-health efforts: screening for pathogens at U.S. airports and responding to infectious-disease outbreaks in the Democratic Republic of the Congo (DRC). The package totals $38.8 million, comprising an $18.8 million contract from the Centers for Disease Control and Prevention (CDC) and a $20 million grant from the U.S. Department of State. The awards are significant both for their size and for the different mechanisms involved: one is a federal contract, while the other is a grant. Contractors and assistance applicants assessing similar work should distinguish the requirements, performance obligations, and oversight structures attached to each mechanism.

The reporting describes XpresTest’s prior work screening travelers for COVID-19 and other infectious diseases at U.S. airports, but says the company has not previously handled Ebola outbreaks or delivered international biosecurity services. XWELL is described as a business whose operations include airport spa services as well as disease-screening activities; reports say most of its revenue in the prior year came from its airport-based spa business. That background makes the awards a reminder that experience in one public-health setting does not automatically demonstrate capability in another. For the airport effort, relevant questions include screening protocols, staffing, laboratory or referral pathways, and continuity across multiple locations. For an international outbreak-response assignment, bidders and oversight teams may also need to assess field operations, local partnerships, logistics, and experience working in challenging environments.

The awards have attracted scrutiny because an investment fund linked to Donald Trump Jr. and Eric Trump reportedly invested approximately $30 million in XWELL months before the federal awards. The reporting says the company’s new awards were roughly seven times the total value of federal contracts XpresTest had directly received before them. These connections and timing are reported context, not proof of improper influence. The supplied reporting says the agencies and company characterized the awards as competitively pursued and does not establish interference in the procurement or grant decision. Procurement professionals should keep those distinctions clear: questions raised by reporting can inform oversight and public accountability, but allegations or associations alone do not establish a procurement violation.

XWELL Chief Executive Officer Ezra Ernst defended the company’s airport screening experience and said the awards were secured through competitive processes, while acknowledging uncertainty about the international assignment. He told ProPublica, “This is a risky contract. I’m not sure we can do it.” That statement underscores why implementation monitoring, milestone review, and transparent reporting matter in specialized public-health work. For companies competing in this market, the practical lesson is to substantiate capability claims with verifiable past performance and to identify how gaps will be addressed through qualified personnel, partners, training, and contingency planning. For agencies and oversight stakeholders, the awards put contractor qualifications, award documentation, and performance risk management in focus. No new solicitation is identified in the supplied material, so the immediate intelligence value is in understanding awarded work and the capabilities that may be scrutinized during execution—not in anticipating an open bid.

• CDC awarded XpresTest an $18.8 million contract for pathogen screening at several U.S. airports.
• The State Department awarded a $20 million grant for infectious-disease outbreak response in the DRC.
• The combined value is $38.8 million; reports describe this as roughly seven times XpresTest’s prior directly received federal contract value.
• Reporting cites XpresTest’s airport experience screening for COVID-19 and other diseases, while noting no prior Ebola outbreak or international biosecurity experience.
• XWELL CEO Ezra Ernst acknowledged the DRC assignment is risky and said, “This is a risky contract. I’m not sure we can do it.”
• An investment fund linked to Donald Trump Jr. and Eric Trump reportedly invested approximately $30 million in XWELL before the awards; the supplied reporting does not establish interference.
• The company and agencies described the awards as competitively pursued, according to the provided material.
• Bidders for comparable work should document relevant past performance, field capacity, staffing, local partnerships, and risk controls.
• Oversight teams should distinguish contract and grant requirements and monitor execution against the applicable award terms.
• No new solicitation is identified; the signal concerns existing awards, contractor capability, and performance oversight.